Background: Bone metastases are common in many types of cancer. As screening methods different imaging modalities are available. A new approach for the screening of osseous metastases represents ...

Zoledronic acid is a potent, new-generation bisphosphonate indicated for the treatment of documented bone metastasis in patients with solid tumors and bone lesions associated with multiple myeloma.

the most common sites of metastasis were: bone (in 54.06% of those with metastatic cancer) lung (in 14.18%) liver (in 10.5%) brain (in 1.6%) Additionally, 19.67% of people had metastasis in ...

Metastasis remains the primary challenge to reducing cancer deaths worldwide. A new MSK study is providing unique insights ...

The average time from consultation to treatment for bone metastases decreased by almost 4 days with virtual simulation ...

Raman is also a member of the Johns Hopkins Kimmel Cancer Center. “We first had to determine whether DDX3 was expressed in ...

In a new study led by Johns Hopkins Medicine, the drug RK-33 has demonstrated promise in treating breast cancer that has spread to the bone (breast cancer bone metastasis). RK-33 was previously ...

Median overall survival (OS) increased from 19.3 months with upfront immune checkpoint inhibition (ICI) to 41.3 months when a ...

Their findings hold promise for advancing the development of preclinical tools to predict breast cancer bone metastasis. Researchers from Tampere University, Finland, and Izmir Institute of ...

After determining that breast cancer bone metastasis cells had high levels of DDX3, the research team turned to mice to test if RK-33 had any effect on the DDX3 protein and function of the cancer ...

Zetagen Therapeutics announces first patients enrolled in phase 2a clinical study of ZetaMet (Zeta-BC-003) for metastatic ...